Intravenous Infusions for Sedation: Rationale, State of the Art, and Future Trends

Intravenous administration of sedatives and analgesics is essential in pediatric sedation, particularly in non-operating room settings. While other routes such as inhalational, oral, intranasal, and intramuscular have their limitations, intravenous administration offers complete systemic absorption, ensuring reliable and consistent effects. This method significantly reduces inter- and intra-individual variability in pharmacokinetics, allowing for precise dosage adjustments based on changing clinical scenarios, such as varying pain levels or patient responsiveness. Agents like propofol, dexmedetomidine, and remifentanil are preferred due to their rapid onset and offset, enabling effective titration of sedation. Propofol is particularly noted for its anxiolytic and antiemetic properties, though it requires careful monitoring due to potential cardiorespiratory depression. Dexmedetomidine provides rousable sedation while maintaining respiratory function, making it suitable for various settings. Ketamine, known for its analgesic and dissociative effects, is valuable, especially in cases of difficult venous access. Remifentanil offers potent analgesia but carries risks of respiratory depression. Target Controlled Infusion systems represent a significant advancement, allowing real-time adjustments based on pharmacokinetic modeling, thereby enhancing stability in sedation levels. However, ongoing research is necessary to refine pediatric sedation protocols and validate pharmacokinetic models that consider children’s unique physiological characteristics. As pediatric sedation practices evolve, a focus on individualized, evidence-based approaches is crucial for improving patient outcomes and safety. The integration of advanced technologies and optimized pharmacological strategies promises to enhance the effectiveness and safety of sedation in diverse clinical environments.